AR115449A1 - Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a - Google Patents

Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a

Info

Publication number
AR115449A1
AR115449A1 ARP190101460A ARP190101460A AR115449A1 AR 115449 A1 AR115449 A1 AR 115449A1 AR P190101460 A ARP190101460 A AR P190101460A AR P190101460 A ARP190101460 A AR P190101460A AR 115449 A1 AR115449 A1 AR 115449A1
Authority
AR
Argentina
Prior art keywords
treatment
adeno
associated viruses
vectors
mucopolysacaridosis
Prior art date
Application number
ARP190101460A
Other languages
English (en)
Inventor
Virginia Areba Haurigot
Sanchez Albert Ribera
Clares Vctor Sanchez
Tubert Mara Ftima Bosch
Original Assignee
Esteve Pharmaceuticals Sa
UNIV AUTòNOMA DE BARCELONA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa, UNIV AUTòNOMA DE BARCELONA filed Critical Esteve Pharmaceuticals Sa
Publication of AR115449A1 publication Critical patent/AR115449A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente proporciona secuencias de polinucleótidos, vectores derivados de virus adenoasociados y composiciones farmacéuticas que contienen los mismos para el tratamiento de trastornos de almacenamiento lisosomal y especialmente, para el tratamiento de mucopolisacaridosis tipo IVA o síndrome de Morquio A.
ARP190101460A 2018-05-30 2019-05-30 Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a AR115449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382373 2018-05-30

Publications (1)

Publication Number Publication Date
AR115449A1 true AR115449A1 (es) 2021-01-20

Family

ID=62530167

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101460A AR115449A1 (es) 2018-05-30 2019-05-30 Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a

Country Status (16)

Country Link
US (1) US20210214695A1 (es)
EP (1) EP3802803A1 (es)
JP (1) JP7369403B2 (es)
KR (1) KR20210027266A (es)
CN (1) CN113474453B (es)
AR (1) AR115449A1 (es)
AU (1) AU2019275969A1 (es)
BR (1) BR112020024377A2 (es)
CA (1) CA3101659A1 (es)
CO (1) CO2020015942A2 (es)
IL (1) IL279054A (es)
MA (1) MA52737A (es)
MX (1) MX2020012911A (es)
PH (1) PH12020552041A1 (es)
SG (1) SG11202011777PA (es)
WO (1) WO2019228950A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3829619A4 (en) * 2018-07-27 2022-05-18 REGENXBIO Inc. TREATMENT OF MUCOPOLYSACCHARIDOSE IVA
JP2023512043A (ja) * 2020-01-29 2023-03-23 レジェンクスバイオ インコーポレーテッド ムコ多糖症ｉｖａの治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255098A1 (en) * 2002-08-07 2004-02-25 Neworgen Limited A novel homo protein with cancer suppressing function and its coding sequence
US7972593B2 (en) * 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
WO2015173308A1 (en) * 2014-05-14 2015-11-19 Laboratorios Del Dr. Esteve S.A. Adenoassociated virus vectors for the treatment of lysosomal storage disorders
WO2018060097A1 (en) * 2016-09-30 2018-04-05 Laboratorios Del Dr. Esteve, S. A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Also Published As

Publication number Publication date
KR20210027266A (ko) 2021-03-10
CN113474453B (zh) 2024-01-12
IL279054A (en) 2021-01-31
JP7369403B2 (ja) 2023-10-26
JP2021526023A (ja) 2021-09-30
TW202016315A (zh) 2020-05-01
CA3101659A1 (en) 2019-12-05
EP3802803A1 (en) 2021-04-14
CN113474453A (zh) 2021-10-01
US20210214695A1 (en) 2021-07-15
BR112020024377A2 (pt) 2021-03-02
WO2019228950A1 (en) 2019-12-05
SG11202011777PA (en) 2020-12-30
MX2020012911A (es) 2021-02-26
MA52737A (fr) 2021-04-14
PH12020552041A1 (en) 2021-06-28
CO2020015942A2 (es) 2021-03-08
AU2019275969A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
AR109752A1 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
CO2020001879A2 (es) Compuesto heterocíclico y su uso
CO2018013738A2 (es) Novedosos virus vaccinia modificados genéticamente
CL2016001889A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
BR112016028255A2 (pt) agentes imunorreguladores
BR112017000550A2 (pt) compostos antiproliferativos e métodos de uso dos mesmos
CR20160555A (es) Vectores de aav para la terapia génica de la retina y el snc
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
CO2020015942A2 (es) Vectores de virus adenoasociados para el tratamiento de mucopolisacaridosis tipo iv a
BR112022011902A2 (pt) Terapias de combinação
BR112017000978A2 (pt) mioinositol e probióticos e usos
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
BR112016022879A2 (pt) ativadores de histona acetiltransferase e usos dos mesmos
UY38472A (es) Moduladores de la expresión de foxp3
BR112017004552A2 (pt) composições farmacêuticas
IL283929A (en) Treatment of 22q11.2 deficiency syndrome with cannabidiol
CU20170134A7 (es) 2-tiopirimidinonas
BR112018069221A2 (pt) rotor de centrífuga com bicos alternados para centrífuga de disco com bicos